News

… [Read more...] about U.S. FDA Accepts COUR Pharmaceuticals Investigational New Drug Application (IND) for a Proof-of-Concept Study for the Treatment of Primary Biliary Cholangitis (PBC)

Today, COUR Pharma announced the U.S. Food and … [Read more...] about FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals

… [Read more...] about COUR’s intracellular T-cell reprograming leads to a reduction to anti-drug and neutralizing antibodies

Late-breaking data presented from a Phase 2a trial … [Read more...] about Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

View Presentation Here … [Read more...] about Presentation: Phase 2 Celiac Disease Data from UEG Week 2019

Cour Pharmaceuticals Receives FDA Fast Track … [Read more...] about Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA

Cour Pharmaceuticals, a specialty pharma company … [Read more...] about Cour Pharmaceuticals Announces an Open Investigational New Drug (IND) Application for TIMP-GLIA – A Novel Treatment for Celiac Disease

 Takeda and Cour Partner to Develop Novel … [Read more...] about Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease